Table 1

Categorical clinical features in the national cohort of paediatric patients with HCM: SD/CA individuals compared with survivors

CharacteristicsSD/CA n=39 (32 for ECG) (% of total)Survivors (surv) n=100 (% of total)p Value Fisher’s exact (SD/CA vs surv)
Proportion male66.762.3n.s.
Syndrome-related HCM15.618.9n.s.
Familial HCM53.362.5n.s.
Family history of sudden death27.630.0n.s.
LVOTO at rest at diagnosis67.936.0 p=0.0044
Cardiac syncope10.015.1n.s.
nsVT on Holter73.710.8 p<0.0001
QRS axis deviation on ECG66.741.0 p=0.015
Pathological T wave inversion61.340.4p=0.06 (n.s.)
Precordial T wave inversion48.427.7 p=0.028
ST depression at rest43.38.4 p<0.0001
Dominant S in V4 65.632.3 p=0.0016
Pre-excitation ECG01.1n.s.
Beta-blocker therapy53.181.8 p=0.0021
Calcium-blocker therapy12.97.0n.s.
Beta-blocker+disopyramide12.930.0p=0.06 (n.s.)
Amiodarone therapy3.25.0n.s.
No medical therapy37.512.0 p=0.0028
Pacing therapy
(for LVOT obstruction)
  • HCM, hypertrophic cardiomyopathy; LVOT, left ventricular outflow tract; LVOTO, left ventricular outflow tract obstruction; n.s., not statistically significant; nsVT, non-sustained ventricular tachycardia; SD/CA, sudden death/cardiac arrest.